Michael Philbin serves as the Director of Value Evidence & Outcomes Strategic Initiatives at Teva Pharmaceuticals, where he leverages his extensive experience in the pharmaceutical industry to drive impactful strategies that enhance product value for managed care payers and healthcare decision-makers. With a robust background...
Michael Philbin serves as the Director of Value Evidence & Outcomes Strategic Initiatives at Teva Pharmaceuticals, where he leverages his extensive experience in the pharmaceutical industry to drive impactful strategies that enhance product value for managed care payers and healthcare decision-makers. With a robust background spanning over two decades in managed care, medical affairs, and health economics outcomes research (HEOR), Michael is adept at navigating the complexities of the healthcare landscape. His role involves facilitating the design, execution, and evaluation of strategic initiatives that align with the needs of US managed care payers, ensuring that Teva’s products are not only clinically effective but also demonstrate clear economic value.
One of Michael's key achievements includes a remarkable 90% increase in the external resources available to the proactive Payer Focused Field Medical Team, enhancing their ability to engage with healthcare customers and optimize product positioning. His expertise extends across multiple therapeutic areas, including cardiology, rheumatology, and neurology, allowing him to contribute significantly to the development of value propositions that resonate with diverse stakeholders. Michael's innovative approach and persistent drive for excellence enable him to identify and implement solutions that address the evolving demands of population health decision-makers.
In addition to his strategic initiatives, Michael's proficiency in clinical research and development, coupled with his deep understanding of health economics, positions him as a thought leader in the industry. His commitment to advancing healthcare outcomes through evidence-based strategies underscores his role as a vital asset to Teva Pharmaceuticals and the broader pharmaceutical community.
